查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1425123

全球子宫内膜异位症治疗市场：预测（2024-2029）

Endometriosis Treatment Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 143 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球子宫内膜异位症治疗市场规模预计将从2022年的14.31亿美元成长到2029年的29.1亿美元，复合年增长率为11.87%。

子宫内膜异位症是一种常见但令人痛苦的疾病，会干扰日常生活。当您患有子宫内膜异位症时，类似子宫内膜的组织会在骨盆和腹部周围生长。除了引起生殖问题外，子宫内膜异位症还会导致疼痛和经期延长。药物疗法和手术通常用于治疗子宫内膜异位症。

子宫内膜异位症盛行率增加

根据世界卫生组织 (WHO) 的数据，全球约有 10%（1.9 亿人）的育龄妇女和青少年受到子宫内膜异位症的影响。骨盆腔极度不适是子宫内膜异位症的常见副作用，尤其是在月经期间。有些人在上厕所或做爱时也可能会感到疼痛。有很多人在怀孕方面遇到困难。子宫内膜异位症是一种复杂的疾病，影响着世界各地从初潮到闭经的许多女性，无论社会地位或文化背景如何。子宫内膜异位症的治疗通常着重于症状管理，因为目前尚无公认的治疗方法。这导致了子宫内膜异位症治疗行业的成长。

增加子宫内膜异位症意识计划

各政府机构正在努力製定计划，为人们提供有关子宫内膜异位症的必要知识。例如，ENPOWR计划是 EndoFound 发起的一项以青少年为中心的倡议，为 9-12 年级的青少年提供月经健康资讯和子宫内膜异位症教育。我是。透过教育可以提高年轻女性对子宫内膜异位症和月经的认识。该宣传活动鼓励护理和医学生及早发现和治疗子宫内膜异位症，从而推动子宫内膜异位症治疗市场的发展。青少年推广计画是子宫内膜异位症协会最重要的教育计画之一，重点关註十几岁的女孩，她们是子宫内膜异位症最脆弱的受害者。可以显着减少这种疾病对您生活的影响。迄今为止，子宫内膜异位症协会已向 34 个州的数千名儿童分发了 2,577 个青少年推广教育套件。

促性腺激素分泌释放激素 (GnRH) 生长

促性腺激素分泌释放激素（GnRH）由内分泌系统脑下垂体分泌，刺激滤泡刺激素和黄体激素的合成。性荷尔蒙睪固酮、雌激素和黄体酮是由这些促性腺激素分泌（荷尔蒙）产生的。性发展、性慾和生育能力取决于 GnRH。 GnRH间接促进女性生殖系统黄体酮和雌激素的内部合成。这些是主要的女性激素，对于怀孕和排卵至关重要。

人工智慧和远端医疗在子宫内膜异位症治疗的应用

近几十年来，通讯和电脑技术已成功应用于医疗保健管理。此外，在COVID-19大流行的第二阶段，这些技术被广泛应用于常规临床实践，特别是在子宫内膜异位症等持续性疾病患者的治疗中。由于大流行的限制，大多数寻求缓解疼痛或不孕症治疗的子宫内膜异位症患者无法去医院。这种情况增加了急性子宫内膜异位症问题的可能性，如肠阻塞、直肠出血、泌尿道出血、囊肿破裂和剧烈腹痛。

在北美，子宫内膜异位症治疗市场预计将稳定成长。

北美子宫内膜异位症治疗市场预计将因该地区子宫内膜异位症盛行率的增加而受到推动。例如，根据妇女健康办公室的说法，当类似于子宫内膜或子宫内膜的组织生长在器官之外时，就会发生子宫内膜异位症。子宫内膜异位症的生长会导致月经期间肿胀和出血。超过 11% 的 15 至 44 岁美国女性可能患有子宫内膜异位症。子宫内膜异位症在 30 多岁和 40 多岁的女性中更为常见，会使怀孕变得更加困难。各种治疗可以减轻症状，也可能增加怀孕的机会。

子宫内膜异位荷尔蒙疗法

  • 荷尔蒙疗法：有多种黄体素荷尔蒙疗法，包括含有levonorgestrel的避孕器（Mirena、Skyla）、植入式植入（Nexplanon）、静脉注射避孕药（Depo-Provera）或黄体素药丸（Camila）。
  • Aromatase抑制剂：一组称为Aromatase抑制剂的药物可透过降低体内雌激素水平来发挥作用。为了控制子宫内膜异位症，医生可能会建议使用含有Aromatase抑制剂和黄体素的荷尔蒙避孕药。
  • 荷尔蒙避孕药、避孕药、贴片和避孕环有助于调节导致子宫内膜组织每月堆积的荷尔蒙。在某些情况下，使用荷尔蒙避孕药，尤其是连续週期疗法，可以减少或消除不适。

FDA核准子宫内膜异位症治疗药物

  • 2023年6月，葛兰素史克公司表示，错配修復缺陷（dMMR）/微卫星不稳定性高（MSI-H）与化疗合併治疗原发性晚期或復发性子宫内膜癌成年患者的Gemperli （dostallimab）的补充生技药品核准申请（sBLA） ）已被美国食品药物管理局（FDA）接受。
  • 2022 年 8 月，Myovant Sciences 和辉瑞公司宣布 MYFEMBREE(R)（relugolix 40mg、雌二醇 1mg、醋酸炔诺酮 0.5mg）已被批准用于治疗闭经女性中度至重度子宫内膜异位症相关疼痛。美国药物管理局 (FDA) 宣布，该药物已获得美国食品药物管理局(FDA)核准作为每日一次、一粒的治疗药物。治疗方法可持续长达 24 个月。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 先决条件

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章子宫内膜异位症治疗市场：依治疗类型

  • 介绍
  • 止痛药
  • 荷尔蒙疗法

第六章子宫内膜异位症治疗市场：依药物类别

  • 介绍
  • NSAID
  • 口服避孕药
  • 其他的

第七章子宫内膜异位症治疗市场：按分销管道

  • 介绍
  • 医院药房
  • 零售药房
  • 其他的

第八章子宫内膜异位症治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 併购/协议/合作
  • 供应商竞争力矩阵

第十章 公司简介

  • Bayer
  • Apollo Cradle
  • Endodiag
  • HCA Healthcare UK
  • EndoFound
  • The Endometriosis Clinic
  • The Endo Co
  • Bupa
  • NYU Langone Health
  • Cromwell Hospital
简介目录
Product Code: KSI061616242

The endometriosis treatment market is expected to grow at a CAGR of 11.87% from US$1.431 billion in 2022 to US$2.91 billion in 2029.

A common yet excruciating condition that can interfere with individuals' everyday lives is endometriosis. When endometriosis is present, tissue that resembles the uterine lining grows in additional places in one's pelvis and abdomen. Endometriosis can cause painful, prolonged periods in addition to reproductive issues. Medication or surgery is often used to treat endometriosis.

Growing prevalence of endometriosis

According to the World Health Organization, approximately 10% (190 million) of women and adolescents of reproductive age worldwide suffer from endometriosis. Extreme pelvic discomfort is a common side effect of endometriosis, particularly during menstruation. Some also experience pain when using the restroom or having intercourse. A few individuals struggle with conception. Regardless of their social standing or cultural background, endometriosis is a complicated illness that affects a large number of women worldwide from the time of their menarche until menopause. Endometriosis therapy often focuses on managing symptoms because there is presently no recognized cure for the condition. This has led to the growth of the endometriosis treatment industry.

Rising endometriosis awareness programs

Various government association is focusing on building programs to provide people with the required knowledge about endometriosis. For instance, The ENPOWR Project is EndoFound's youth-focused effort to provide menstrual health information and endometriosis education to teenagers in grades 9 through 12. Young women's understanding of endometriosis and dysmenorrhea can be improved by education. The campaign encouraged nursing and medical students to seek care for endometriosis early identification and management boosting the endometriosis treatment market. The Teen Outreach Programme is one of the Endometriosis Association's most significant educational programs because it focuses on teenage girls who are the disease's most susceptible victims and can significantly lessen the disease's effects on their lives. The association has given out 2,577 Teen Outreach instructional kits to thousands of children throughout 34 states.

Growth of Gonadotropin-Releasing Hormone (GnRH)

Gonadotropin-releasing hormone (GnRH) is used by the pituitary gland in the endocrine system to promote the synthesis of follicle-stimulating hormone and luteinizing hormone. The sex hormones testosterone, estrogen, and progesterone are produced by these gonadotropins (hormones). Sexual development, sex drive, and fertility depend on GnRH. GnRH indirectly promotes the body's synthesis of progesterone and estrogen in the female reproductive system. These are the main female sex hormones, and they are essential for conception and ovulation.

Artificial Intelligence and Telemedicine in the Treatment of Endometriosis

Communication and computer-based technologies have been successfully applied to healthcare administration in recent decades. Additionally, during the COVID-19 epidemic 2, these technologies were widely used in regular practice, particularly for the management of patients with persistent illnesses like endometriosis. Most endometriosis patients seeking treatment for pain alleviation or infertility were unable to visit hospitals due to pandemic limitations. The possibility of acute endometriosis problems such as intestinal blockage, rectal or urinary bleeding, cyst rupture, and excruciating abdominal pain was raised by this circumstance.

In North America, it is projected that the endometriosis treatment market will grow steadily.

The endometriosis treatment market in North America is anticipated to be fueled by the growing prevalence of endometriosis in the region. For instance, according to the Office on Women's Health, when tissue that resembles the lining within the uterus or womb grows outside of those organs it might lead to endometriosis. Endometriosis growths may swell and bleed throughout the menstrual period. It may affect more than 11 percent of American women between the ages of 15 and 44. It is more common in women in their 30s and 40s and may make getting pregnant more challenging. The symptoms may be controlled with a variety of treatments, which can also increase one's chances of getting pregnant.

Endometriosis Hormone Therapy

  • Progestin Therapy, Numerous progestin treatments, such as an intrauterine device with levonorgestrel (Mirena, Skyla), a contraceptive implant (Nexplanon), an intravenous contraceptive (Depo-Provera), or a progestin pill (Camila).
  • Aromatase Inhibitors, a group of medications known as aromatase inhibitors work to lower the level of estrogen in the body. To manage endometriosis, the doctor may advise using a combination hormonal contraception that combines an aromatase inhibitor with a progestin.
  • Hormonal Contraceptives, Birth control pills, patches, and vaginal rings assist regulate the hormones that cause the monthly accumulation of endometrial tissue. In some circumstances, using hormonal contraceptives, particularly continuous-cycle regimens, may lessen or eliminate discomfort.

FDA Approvals for Endometriosis Treatment Drugs

  • In June 2023, the supplemental Biologics Licence Application (sBLA) for Jemperli (dostarlimab) in combination with chemotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer was accepted by the US Food and Drug Administration (FDA), according to GSK plc.
  • In August 2022, Myovant Sciences and Pfizer Inc. announced that MYFEMBREE® (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) has been approved by the U.S. Food and Drug Administration (FDA) as a once-daily, one-pill treatment for the management of moderate to severe endometriosis-related pain in premenopausal women. The treatment regimen may last up to 24 months.

Market Key Developments

  • In February 2022, to commercialize and market Linzagolix, an oral GnRH antagonist, ObsEva SA, a biopharmaceutical business researching and commercializing innovative medicines for women's health, and Theramex, a top global pharmaceutical firm specializing in women's health, have entered into a licensing agreement.
  • In November 2021, Organon and Forendo Pharma announced that they had signed a legally binding agreement under which Organon would acquire Forendo, a clinical-stage pharmaceutical firm that specializes in cutting-edge therapies for women's health.

Segmentation:

By Treatment Type

  • Pain Medication
  • Hormone Therapy

By Drug Class

  • NSAIDs
  • Oral Contraceptive
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Assumptions

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Force Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. ENDOMETRIOSIS TREATMENT MARKET, BY TREATMENT TYPE

  • 5.1. Introduction
  • 5.2. Pain Medication
  • 5.3. Hormone Therapy

6. ENDOMETRIOSIS TREATMENT MARKET, BY DRUG CLASS

  • 6.1. Introduction
  • 6.2. NSAIDs
  • 6.3. Oral Contraceptive
  • 6.4. Others

7. ENDOMETRIOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacy
  • 7.3. Retail Pharmacy
  • 7.4. Others

8. ENDOMETRIOSIS TREATMENT MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. The Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Israel
    • 8.5.4. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. Bayer
  • 10.2. Apollo Cradle
  • 10.3. Endodiag
  • 10.4. HCA Healthcare UK
  • 10.5. EndoFound
  • 10.6. The Endometriosis Clinic
  • 10.7. The Endo Co
  • 10.8. Bupa
  • 10.9. NYU Langone Health
  • 10.10. Cromwell Hospital